Clinical trials: Nicotine
Chemo Brain, Chemotherapy-related Cognitive Impairment
Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study
The purpose of this study is to evaluate the use of a nicotine patch as a treatment for problems with attention, learning and memory in breast cancer patients who are 1-5 years post chemotherapy.
- Conditions
- Chemo Brain, Chemotherapy-related Cognitive Impairment, Chemo Fog, Breast Cancer
- Trial name
- NCT02312934
- Testing
- Transdermal nicotine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Vanderbilt University Medical Center
Smoking Cessation
Varenicline and Nicotine Interactions in Humans (VA)
To examine the effects of varenicline on the subjective, physiological and cognitive responses to intravenous nicotine. Varenicline is a partial nicotine agonist and it is approved as a treatment for smoking cessation.
- Trial name
- NCT00606892
- Testing
- Varenicline, IV Nic
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Yale University
Nicotine Dependence
The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users
This study will help determine if menthol administered by inhalation via electronic cigarettes (e-cigarette) changes the reinforcing effects of pure nicotine administered intravenously in cigarette smokers who smoke mentholated…
- Trial name
- NCT02102100
- Testing
- nicotine, menthol
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Yale University
Tobacco Dependence
Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy
The purpose of this study is to assess the efficacy and safety of a novel nicotine product for continuous abstinence from smoking.
- Trial name
- NCT02355665
- Testing
- Nicotine Spray
- Where
- 8 sites in United States
- Volunteers
- 1,198 people
- Sponsor
- McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study
The overall goal of the present project is to investigate whether lisdexamphetamine (LDX; Vyvanse) is an effective adjunct to nicotine replacement therapy (NRT) to promote smoking cessation in patients with comorbid Attention…
- Trial name
- NCT00736255
- Testing
- Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Duke University
Smoking, Smoking Cessation
QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt
Cigarette smoking constitutes the greatest preventable cause of mortality and morbidity in the US. The most critical period for long term success of smoking cessation appears to be in the first 7 days after the quit date.
- Conditions
- Smoking, Smoking Cessation, Craving, Addiction
- Trial name
- NCT04159571
- Testing
- Real TBS to the vmPFC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Nicotine Use Disorder
Effects of E-cigarette Flavors on Youth TCORS 2.0
This study is an examination of the influence of sweet and cooling flavors on the appeal and abuse potential of nicotine-containing e-cigarettes among susceptible youth.
- Trial name
- NCT03634839
- Testing
- Flavoring Agents, Nicotine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Yale University
Smoking, Smoking Cessation
Implementation Science to Reduce the Disparity in Tobacco Treatment Among Individuals With Serious Mental Illness
This is a pilot trial to examine the feasibility and preliminary effect of a multilevel intervention 'Nudges to Quit' on smoking cessation in patients with serious mental illness who smoke in a community mental health center…
- Conditions
- Smoking, Smoking Cessation, Tobacco Use Cessation
- Trial name
- ISRAISE (NCT05952401)
- Testing
- Usual Care, "Nudges"
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Washington University School of Medicine
Electronic Cigarette Use
Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems
This is a randomized, parallel-group open-label trial to evaluate respiratory symptoms in ENDS users switching from banned flavors to a non-banned flavor (tobacco) or 'tobacco free' nicotine pouches.
- Trial name
- CRoFT (NCT05423340)
- Testing
- E-cigarette Flavor, Tobacco Free Nicotine Pouch
- Where
- United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Smoking Cessation
Suvorexant to Reduce Symptoms of Nicotine Use
The purpose of this study is to assess the impact of suvorexant on established measures of smoking relapse risk (craving,withdrawal, stress reactivity, latency to self-administration) and to validate the somnolent effect of…
- Trial name
- NCT04234997
- Testing
- Suvorexant 20 mg, Suvorexant 0mg
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- The University of Texas Health Science Center, Houston
Nicotine Dependence
Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging
The proposed research will provide significant new gender-specific information of scientific and clinical relevance on the function of the mu-opioid system in nicotine dependence and therapeutic effectiveness of nicotine…
- Trial name
- NCT01664741
- Testing
- Nicotine patch - transdermal
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Nicotine Dependence
Cessation Screening Project
This project will use the Multiphase Optimization Strategy (MOST) to guide the development of optimized treatment strategies for the two most effective smoking cessation medications (Combination Nicotine Replacement [C-NRT] and…
- Trial name
- NCT04188873
- Testing
- Preparation Varenicline and Standard Duration Varenicline, Preparation Varenicline and Extended Duration Varenicline, Standard Duration Varenicline
- Where
- 2 sites in United States
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Electronic Cigarette Use
Assessing the Effect of Nicotine Reduction on ENDS User's Addiction and Exposures
The rapid increase of electronic nicotine delivery systems (ENDS) use by young people in the US and their potential to harm health, cause addiction, and serve as a risk for cigarette smoking or dual-use is alarming.
- Trial name
- NCT05205382
- Testing
- 5% nicotine (Partial Nicotine Reduction), 3% or 2.4% nicotine (Partial Nicotine Reduction), 5% nicotine (Total Nicotine Reduction)
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Florida International University
Positron Emission Tomography
Brain Nicotine Receptor Density in Veteran Smokers
Cigarette smoking is more prevalent among Veterans (27%) than the general U.S. population (21%). Smoking is common among people who use marijuana or caffeine heavily, and the use of menthol cigarettes is becoming increasingly…
- Trial name
- BNRDVS (NCT01721473)
- Testing
- positron emission tomography scan
- Where
- 2 sites in United States
- Volunteers
- 184 people
- Sponsor
- VA Office of Research and Development
Nicotine Addiction, Panic Attack
Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine
The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks.
- Trial name
- DCS/PSRT (NCT01944423)
- Testing
- d-cycloserine, Nicotine replacement therapy, Panic and Smoking Reduction Treatment
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Smoking Cessation
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
Nicotine replacement therapy (NRT) is a well-tolerated and efficacious smoking cessation treatment, and yet many smokers fail to quit using NRT.
- Trial name
- ConNic3 (NCT00894166)
- Testing
- Nicotine Patches, Nicotine patches, then bupropion & nicotine patches (Pre-Quit), Nicotine patches, then varenicline (Pre-Quit)
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Duke University
Nicotine Dependence
Effects of Varenicline on Smoking Reminders
Varenicline is the best smoking cessation agent to date; however it is only effective in a subgroup of smokers and is associated with undesirable side effects in other subgroups.
- Trial name
- VSMK (NCT01524627)
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- University of Pennsylvania
Down Syndrome, Mild Cognitive Impairment
Nicotine Treatment of Cognitive Decline in Down Syndrome
This study will ascertain whether nicotine is safe and tolerable in DS patients, help with dose-ranging of nicotine in DS, look for evidence of enhancements in cognitive functioning, and establish evidence for biological and…
- Trial name
- NCT01778946
- Testing
- Low Dose Nicotine (7mg), Moderate Dose Nicotine (14mg)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt University Medical Center
Smoking, Nicotine Dependence
Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain
This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight…
- Trial name
- NCT00129246
- Testing
- Naltrexone, Bupropion
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID)
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
This study will evaluate the safety and effectiveness of insulin-like growth factor-1 (IGF-1) to treat patients with X-linked severe combined immunodeficiency (XSCID).
- Conditions
- Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
- Trial name
- NCT00490100
- Testing
- Increlex
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)